Shares of Bio-Techne Corporation (NASDAQ: TECH) surged over 5% in pre-market trading on Tuesday, after the life sciences company reported better-than-expected financial results for the first quarter of fiscal 2025.
For the three months ended September 30, 2024, Bio-Techne posted adjusted earnings per share of $0.42, surpassing analysts' consensus estimate of $0.38. Total revenue rose to $289.5 million, exceeding the forecasted $280.3 million.
The strong performance was driven by robust demand across Bio-Techne's product portfolio, particularly in its core Protein Sciences segment. The company also cited favorable foreign exchange rates as a tailwind.
"Bio-Techne's first quarter results reflect the continued execution of our core strategic priorities," said CEO Chuck Kummeth. "We are well-positioned to capitalize on growing end-market opportunities and remain committed to delivering long-term sustainable growth."免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。